====Calithera Biosciences (CALA) : Fast Track designation for CB-839 in combination with cabozantinib

Calithera Biosciences announces that the FDA has granted Fast Track designation to CB-839 in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma